MedTrace Logo

Continuous Monitoring of Vital Signs at Home (WARD HOME II)

NCT06077851 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 83

Last updated 2026-03-13

No results posted yet for this study

Summary

The study aims to investigate the use of wireless, continuous monitoring in patients at home including the frequency of alarms triggered by abnormal vital parameters and their significance for (re)hospitalisation/Serious Adverse Events(SAE) and/or death within 30 days.

Conditions

  • Vital Sign Monitoring
  • Clinical Deterioration
  • Hospital At Home

Interventions

DEVICE

Continuously monitoring

Included patients are monitored with WARD equipment the first days after discharge. Monitoring will last for a maximum of three days.

Sponsors & Collaborators

  • Rigshospitalet, Denmark

    collaborator OTHER

  • Technical University of Denmark

    collaborator OTHER

  • Emergency Medical Services, Capital Region, Denmark

    collaborator OTHER_GOV

  • Bispebjerg Hospital

    lead OTHER

Principal Investigators

  • Emilie Sigvardt, MD · Bispebjerg Hospital

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-10-03
Primary Completion
2025-10-30
Completion
2025-11-30

Countries

  • Denmark

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06077851 on ClinicalTrials.gov